Dexamethasone postoperative

Phase 3Small molecule

EEmory University

Dexamethasone postoperative is one of 10 small molecule programs targeting Steroid. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

SteroidRecruiting

SteroidPhase 3

Recruiting

Competition

Competitive Landscape

10 competitors in Steroid

#DrugCompanyPhaseTrials

Decadron

AAspen Global Incorporated

Approved

6 2

Flagyl

DDePuy Orthopaedics

Phase 3

1 3

Systemic Corticosteroids

Merck & Co.

Phase 3

1 4

Dexamethasone postoperative

EEmory University

Phase 3

1 5

Avodart

Akero Therapeutics

Preclinical

1 6

Zoladex

TTerSera Therapeutics LLC

Preclinical

1 7

Gnrh Ant

Merck & Co.

Preclinical

1 8

Methylprednisolone and Prednisone

Astellas

Phase 1

1 9

Anastrazole

AstraZeneca

Preclinical

1 10

Olux

HHarrow Inc

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Steroid1 trial

Perioperative Steroid Dosing on the APR in AIS

Recruiting·EEmory University·Phase 4·NCT05561725·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Dexamethasone postoperative. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Dexamethasone postoperative compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Dexamethasone postoperative. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Emory University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: EEmory University

Dexamethasone postoperative

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Steroid1 trial

References

Drug Info

Quick Facts

Related News